<SEC-DOCUMENT>0001628280-20-013756.txt : 20201118
<SEC-HEADER>0001628280-20-013756.hdr.sgml : 20201118
<ACCEPTANCE-DATETIME>20200918171531
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001628280-20-013756
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib49cd974770947f785b0ced1e2458e11_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:0.24pt;"><img alt="cumberlandlogo1.jpg" src="cumberlandlogo1.jpg" style="height:79px;width:280px;"></div></div><div style="text-align:center;margin-top:6pt;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-top:6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">September 18, 2020</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">VIA EDGAR CORRESPONDENCE</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Ms. Jeanne Baker</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Division of Corporation Finance</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">United States Securities and Exchange Commission</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">100 F Street, N.E.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Washington, D.C. 20549</font></div><div><font><br></font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">RE&#58;      Cumberland Pharmaceuticals Inc.  </font></div><div style="padding-left:108pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Form 10-K for the Fiscal year Ended December 31, 2019 and Form 8-K filed May 20, 2020 </font></div><div style="text-indent:72pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">File No. 001-33637</font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Ms. Baker&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This letter is provided on behalf of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), in response to comments from the staff of the Division of Corporation Finance (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;) in a letter dated July 8, 2020 to Michael Bonner with respect to the Company&#8217;s Form 10-K for the Fiscal Year Ended December 31, 2019, File No. 001-33637, which was filed by the Company on March 20, 2020 (&#8220;Form 10-K&#8221;), and Form 8-K, File No. 001-33637, which was filed by the Company on May 20, 2020 (&#8220;Form 8-K&#8221;). This letter is a follow up to the response letter provided by the Company to the Staff on July 22, 2020.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Commission&#8217;s numbered comments are set forth below in italics, with the Company&#8217;s responses immediately following. Defined terms used herein and not otherwise defined herein have the meanings given to them in the Form 10-K.</font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">* * * * *</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Item 2.02 Form 8-K filed May 20, 2020</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 99.1, page 10</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Comment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#58;  Please explain how you determine the adjustment for the &#8220;impact of Vibativ cost of product sold&#8221; to arrive at your non-GAAP measure, Adjusted Earnings from continuing operations. For example, clarify whether the adjustment relates to the entirety of the $21,550,000 of inventory acquired that is allocated to cost of sales for the periods presented. Explain to us how it represents a non-cash impact and why you characterize the inventory as being acquired at no additional cost to the consideration paid to Theravance. Please tell us the remaining amount of inventory you expect to impact this measure in future periods and how long you expect it to be a material adjustment. Tell us how you considered Rule 100(b) of Regulation G in evaluating the propriety of the adjustment, given the net revenue for Vibativ included in net income and adjusted earnings from the sale of this inventory in the periods presented.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Response&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> In response to the Staff&#8217;s comments and the Company&#8217;s conversations with the Staff, the Company is respectfully providing the following additional information and response. </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In management&#8217;s calculations of Adjusted Earnings, beginning  with the fourth quarter of 2018, there has been an adjustment for the &#8220;impact of Vibativ</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> cost of product sold&#8221; related to the amount of finished goods inventory that was allocated as a &#8220;costs of sales&#8221; expense associated with shipments of Vibativ. This is a non-cash item, as a significant amount of finished goods inventory was included in the payment for the assets acquired when the Company purchased the Vibativ brand from Theravance Biopharma (&#8220;Theravance&#8221;) during 2018. The finished goods are being expensed as a cost of sales during each period as the inventory is sold. Because it represents a non-cash expense, the Company had previously added it back in the calculation of Adjusted Earnings. </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Management had additional discussions with the Staff on Rule 100(b) of Regulation G, after the Company&#8217;s July 22, 2020 response letter.  Based on these discussions, the Company will include descriptions, discussions and quantifications of the non-cash Vibativ cost of product sold in future earnings reports and commentary on operating results, rather that include the impact of Vibativ cost of product sold as an add-back to the calculation of Adjusted Earnings in future filings with the Commission. Management makes this change given the recurring nature of the non-cash Vibativ cost of product sold expense.  The Company will make this change beginning with our reporting of results for the quarter ended September 30, 2020.   </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">* * * * *</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company acknowledges that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the Company is responsible for the adequacy and accuracy of the disclosure in the filing&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">            We trust that Company has been responsive to the Commission&#8217;s comments.  If you have any questions or would like further information concerning the Company&#8217;s responses to your comment letter, please do not hesitate to contact me at (615) 255-0068.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                                                                        Sincerely,</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                                                                        CUMBERLAND PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                                                                        </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Michael Bonner                                                     </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                                                                        Name&#58; Michael Bonner</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">                                                                        Title&#58; Chief Financial Officer</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>cumberlandlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cumberlandlogo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A;BY,:6-K
M=&5I9P    60 P "    %   $*:0!  "    %   $+J2D0 "     S,U  "2
MD@ "     S,U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBC(]: "BC-&1ZT
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M*3)/M]: '44PD]N>:=DT +13<YZ4$M^M "XHQ29/XT9]:-0'8HIN3GGBES0
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MBMICB.7=D@'H2*Z8'@$=QS3;>P[(XGXC?#:S\<::6!^S:E&#Y-PG!^A]JU/
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
